{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:21:44Z","timestamp":1787678504746,"version":"build-2784847793"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014883","name":"China National Nuclear Corporation","doi-asserted-by":"publisher","award":["ZHYLZD2025013"],"award-info":[{"award-number":["ZHYLZD2025013"]}],"id":[{"id":"10.13039\/501100014883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014883","name":"China National Nuclear Corporation","doi-asserted-by":"publisher","award":["2025FZBCY07"],"award-info":[{"award-number":["2025FZBCY07"]}],"id":[{"id":"10.13039\/501100014883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014883","name":"China National Nuclear Corporation","doi-asserted-by":"publisher","award":["CNNC-JCKY-202605"],"award-info":[{"award-number":["CNNC-JCKY-202605"]}],"id":[{"id":"10.13039\/501100014883","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110189","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:04:04Z","timestamp":1782774244000},"page":"110189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A novel radionuclide probe targeting FN-EDB: a new strategy for radioactive iodine-refractory differentiated thyroid cancer"],"prefix":"10.1016","volume":"180","author":[{"given":"Xue","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongkun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2026.110189_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid Cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110189_bb0010","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110189_bb0015","first-page":"1","article-title":"Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer","volume":"13","author":"Gianoukakis","year":"2024","journal-title":"Eur. Thyroid J."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110189_bb0020","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"issue":"24","key":"10.1016\/j.bioorg.2026.110189_bb0025","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000033878","article-title":"Clinical role of 18F-FDG PET\/CT for detection of radioactive iodine refractory differentiated thyroid cancer","volume":"102","author":"Tang","year":"2023","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110189_bb0030","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1089\/thy.2019.0450","volume":"30","author":"Parihar","year":"2020","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110189_bb0035","first-page":"270","article-title":"Exploring the role of 68Ga-DOTAGA-IAC and comparison of its diagnostic performance with 18F-FDG PET\/CT in radioiodine refractory differentiated thyroid carcinoma","volume":"40","author":"Kumar","year":"2025","journal-title":"Cancer Biother. Radiopharm."},{"issue":"72","key":"10.1016\/j.bioorg.2026.110189_bb0040","first-page":"1","article-title":"Evaluation of integrin \u03b1v\u03b23-targeted imaging for predicting disease progression in patients with high-risk differentiated thyroid cancer (using 99mTc-3PRGD2)","volume":"22","author":"Liang","year":"2022","journal-title":"Cancer Imaging"},{"issue":"896287","key":"10.1016\/j.bioorg.2026.110189_bb0045","first-page":"1","article-title":"Peptide receptor radionuclide therapy in thyroid cancer","volume":"13","author":"Gubbi","year":"2022","journal-title":"Front. Endocrinol."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110189_bb0050","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/MNM.0b013e328364eaab","article-title":"Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET\/CT imaging in well-differentiated thyroid cancer","volume":"34","author":"Ocak","year":"2013","journal-title":"Nucl. Med. Commun."},{"issue":"93","key":"10.1016\/j.bioorg.2026.110189_bb0055","first-page":"1","article-title":"PSMA expression level predicts differentiated thyroid cancer aggressiveness and patient outcome","volume":"9","author":"Martina","year":"2019"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110189_bb0060","article-title":"PSMA expression by microvasculature of thyroid tumors \u2013 potential implications for PSMA theranostics scientific reports","volume":"7","author":"Andrey","year":"2017"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110189_bb0065","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/MNM.0000000000002036","article-title":"Head-to-head comparison of 18F fluorodeoxyglucose PET\/CT and 68Ga-prostate specific membrane antigen-11 PET\/CT in radioactive iodine refractory differentiated thyroid cancer","volume":"46","author":"Kibar","year":"2025","journal-title":"Nucl. Med. Commun."},{"issue":"1160","key":"10.1016\/j.bioorg.2026.110189_bb0070","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1259\/bjr.20230291","article-title":"The value of gallium-68 prostate-specific membrane antigen PET\/CT and 2-18fluoro-2-deoxy-D-glucose PET\/CT in the detection of thyroid cancer lesions: a prospective head-to-head comparison","volume":"97","author":"Shi","year":"2024","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.bioorg.2026.110189_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.648187","article-title":"Fibroblast activation protein-\u03b1 as a target in the bench-to-bedside diagnosis and treatment of tumors: a narrative review","volume":"11","author":"Xin","year":"2021","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110189_bb0080","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"39","author":"Allison","year":"2020","journal-title":"Cancer Metastasis Rev."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110189_bb0085","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/RLU.0000000000003730","article-title":"68Ga-FAPI PET\/CT versus 18F-FDG PET\/CT for detecting metastatic lesions in a case of radioiodine-refractory differentiated thyroid Cancer","volume":"46","author":"Fu","year":"2021","journal-title":"Clin. Nucl. Med."},{"issue":"03","key":"10.1016\/j.bioorg.2026.110189_bb0090","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1055\/a-2185-7746","article-title":"FAPI PET\/CT provides higher uptake and better target to back ground in recurrent and metastatic tumors of patients with iodine refractory papillary thyroid cancer compared with FDG PET CT","volume":"64","author":"Nourbakhsh","year":"2025","journal-title":"Nuklearmedizin - NuclearMedicine"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110189_bb0095","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/RLU.0000000000005301","article-title":"68Ga-FAPI-RGD PET\/CT detected skull metastasis better than 18F-FDG in a patient with radioiodine-refractory differentiated thyroid Cancer","volume":"49","author":"Chen","year":"2024","journal-title":"Clin. Nucl. Med."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110189_bb0100","first-page":"610","article-title":"68Ga-DOTA-FAPI-04 PET\/CT imaging in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients","volume":"36","author":"Chen","year":"2022"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110189_bb0105","first-page":"1","article-title":"Comparison of diagnostic performance of [68Ga]-Ga-FAPI-46 and [18F]-FDG PET\/CT imaging for the detection of lesions and disease staging in patients with breast cancer","volume":"13","author":"Radmehr","year":"2025","journal-title":"Asia Oceania J. Nucl. Med. Biol."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110189_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/mmr.2025.13525","article-title":"Exploring the mechanism of fibronectin extra domain B in the tumor microenvironment and implications for targeted immunotherapy and diagnostics (review)","volume":"31","author":"Zhou","year":"2025","journal-title":"Mol. Med. Rep."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110189_bb0115","doi-asserted-by":"crossref","first-page":"941","DOI":"10.7150\/thno.44948","article-title":"Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma","volume":"11","author":"Saw","year":"2021","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110189_bb0120","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1158\/1535-7163.MCT-22-0099","article-title":"Anti-extra domain B splice variant of fibronectin antibody\u2013drug conjugate eliminates tumors with enhanced efficacy when combined with checkpoint blockade","volume":"21","author":"Hooper","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110189_bb0125","first-page":"2100","article-title":"EDB-FN targeted probes for the surgical navigation, radionuclide imaging, and therapy of thyroid cancer","author":"Ruping","year":"2023","journal-title":"Original Article"},{"issue":"24","key":"10.1016\/j.bioorg.2026.110189_bb0130","first-page":"1","article-title":"L19-conjugated gold nanoparticles for the specific targeting of EDB-containing fibronectin in neuroblastoma","volume":"18","author":"Barisione","year":"2025","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110189_bb0135","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/CAD.0000000000000938","article-title":"The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors","volume":"31","author":"Corbellari","year":"2020","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bioorg.2026.110189_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122798","article-title":"A single-chain fab derived drug conjugate for HER2 specific delivery","volume":"313","author":"Xu","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioorg.2026.110189_bb0145","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.matbio.2024.12.009","article-title":"Anticancer effect of a single-chain variable fragment against pro-matrix metalloproteinase-7 in colon cancer","volume":"135","author":"Min","year":"2025","journal-title":"Matrix Biol."},{"key":"10.1016\/j.bioorg.2026.110189_bb0150","first-page":"273","article-title":"Injection of ROS-responsive hydrogel loaded with IL-1\u03b2-targeted nanobody for ameliorating myocardial infarction","volume":"46","author":"Wang","year":"2025","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.bioorg.2026.110189_bb0155","first-page":"1","article-title":"Biological evaluation of 131I and CF750-labeled Dmab(scFv)-fc antibodies for xenograft imaging of CD25-positive tumors","author":"Qing","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bioorg.2026.110189_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.675014","article-title":"Theranostic terbium radioisotopes: challenges in production for clinical application","volume":"8","author":"Naskar","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.bioorg.2026.110189_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2024.1472500","article-title":"Terbium sisters: current development status and upscaling opportunities","volume":"4","author":"Moiseeva","year":"2024","journal-title":"Front. Nucl. Med."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110189_bb0170","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.7150\/thno.92775","article-title":"Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside","volume":"14","author":"Van Laere","year":"2024","journal-title":"Theranostics"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110189_bb0175","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.3390\/molecules28073155","article-title":"Preclinical evaluation of [155\/161Tb]Tb-crown-TATE\u2014A novel SPECT imaging theranostic agent targeting neuroendocrine tumours","volume":"28","author":"Wharton","year":"2023","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110189_bb0180","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jconrel.2012.08.029","article-title":"Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging","volume":"163","author":"Park","year":"2012","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110189_bb0185","first-page":"1","article-title":"Antibody-based delivery of interleukin-2 modulates the immunosuppressive tumor microenvironment and achieves cure in pancreatic ductal adenocarcinoma syngeneic mice","volume":"44","author":"Carbone","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110189_bb0190","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s12149-020-01472-9","article-title":"In vitro\/in vivo assessment of the targeting ability of [99mTc] Tc-labeled an aptide specific to the extra domain B of fibronectin (APTEDB) for colorectal cancer","volume":"34","author":"Ranjbar","year":"2020","journal-title":"Ann. Nucl. Med."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110189_bb0195","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00259-019-04345-0","article-title":"Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer","volume":"46","author":"M\u00fcller","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110189_bb0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13550-016-0171-1","article-title":"Contribution of auger\/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of 161Tb-folate and 177Lu-folate","volume":"6","author":"Haller","year":"2016","journal-title":"EJNMMI Res."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110189_bb0205","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2967\/jnumed.115.170423","article-title":"Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: implications for radiopharmaceutical therapy","volume":"57","author":"Hindi\u00e9","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110189_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/mp.18035","article-title":"Framework to calculate 225Ac 177Lu and 161Tb radiation dose and biological effect in metastatic castration-resistant prostate cancer treatment","volume":"52","author":"Ghaseminejad","year":"2025","journal-title":"Med. Phys."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110189_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040536","article-title":"Simultaneous visualization of 161Tb- and 177Lu-labeled somatostatin analogues using dual-isotope SPECT imaging","volume":"13","author":"Borgna","year":"2021","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110189_bb0220","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","article-title":"Combination of terbium-161 with somatostatin receptor antagonists\u2014a potential paradigm shift for the treatment of neuroendocrine neoplasms","volume":"49","author":"Borgna","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110189_bb0225","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00259-014-2798-3","article-title":"Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model","volume":"41","author":"Gr\u00fcnberg","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110189_bb0230","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1007\/s00259-023-06147-x","article-title":"EDB-FN targeted probes for the surgical navigation, radionuclide imaging, and therapy of thyroid cancer","volume":"50","author":"Li","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110189_bb0235","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.2967\/jnumed.107.040477","article-title":"Small-animal PET of tumor angiogenesis using a 76Br-labeled human recombinant antibody fragment to the EDB domain of fibronectin","volume":"48","author":"Rossin","year":"2007","journal-title":"J. Nucl. Med."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110189_bb0240","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2008-06-160416","article-title":"Expression of the oncofetal EDB-containing fibronectin isoform in hematologic tumors enables EDB-targeted 131I-L19-SIP radioimmunotherapy in Hodgkin lymphoma patients","volume":"113","author":"Sauer","year":"2009","journal-title":"Blood"},{"issue":"22056","key":"10.1016\/j.bioorg.2026.110189_bb0245","first-page":"1","article-title":"EDB-FN-targeted probes for near infrared fluorescent imaging and positron emission tomography imaging of breast cancer in mice","volume":"14","author":"Zhang","year":"2024","journal-title":"Sci. Rep."},{"issue":"19","key":"10.1016\/j.bioorg.2026.110189_bb0250","doi-asserted-by":"crossref","first-page":"7053s","DOI":"10.1158\/1078-0432.CCR-1004-0015","article-title":"Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate","volume":"11","author":"Berndorff","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110189_bb0255","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.7150\/thno.92273","article-title":"161Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to 177Lu-PSMA-617","volume":"14","author":"Schaefer-Schuler","year":"2024","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110189_bb0260","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00259-024-06963-9","article-title":"EANM expert opinion: how can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose\u2013response and threshold absorbed doses","volume":"52","author":"Pouget","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"13","key":"10.1016\/j.bioorg.2026.110189_bb0265","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1007\/s00259-024-06827-2","article-title":"Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting","volume":"51","author":"Busslinger","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600725X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600725X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:51:45Z","timestamp":1787676705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682600725X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":53,"alternative-id":["S004520682600725X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110189","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel radionuclide probe targeting FN-EDB: a new strategy for radioactive iodine-refractory differentiated thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110189","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110189"}}